Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone

Over a lifetime horizon AspyreRx plus standard of care was estimated to be superior to SoC alone providing more life years and improvements in quality of life at a lower cost


Study suggests that...

Related Keywords

United States ,American ,Niall Davison ,Frank Karbe ,Nasdaq ,Exchange Commission ,American Diabetes Association ,Institute For Clinical ,Senior Scientific Lead At Maple Health Group ,Better Therapeutics Inc ,Better Therapeutics ,Effectiveness Analysis ,Prescription Digital Therapeutic ,Economic Review ,Senior Scientific Lead ,Maple Health ,Better Therapeutic ,Markets ,